Atezolizumab Plus Chemo Significantly Improves pCR Rates in Early TNBC, Irrespective of PD-L1 Status
September 20th 2020The addition of neoadjuvant atezolizumab to nab-paclitaxel plus doxorubicin and cyclophosphamide significantly improved pathologic complete responses in patients with stage 2 or stage 3 triple-negative breast cancer, compared with placebo plus chemotherapy.
HAIC Shows Better Efficacy and Safety in Unresectable HCC Versus Standard of Care
Overall survival was significantly improved in patients who received hepatic arterial infusion chemotherapy with oxaliplatin, fluorouracil, and leucovorin compared with transarterial chemoembolization.
Frontline Lorlatinib Bests Crizotinib in Advanced ALK+ NSCLC
First-line treatment with the third-generation ALK TKI lorlatinib significantly improved progression-free survival, and also was associated with higher overall and intracranial response rates, compared with crizotinib in patients with ALK-positive non–small cell lung cancer.
Abemaciclib/Tamoxifen Shows OS Benefit in HR+, HER2- Metastatic Breast Cancer
September 20th 2020The addition of tamoxifen to abemaciclib resulted in an improvement in overall survival compared with abemaciclib monotherapy in in patients with hormone receptor–positive, HER2-negative metastatic breast cancer, with benefit observed across all patient subgroups.
Sacituzumab Govitecan Significantly Improves Survival in Metastatic TNBC
Treatment with sacituzumab govitecan led to a 59% reduction in the risk of disease progression or death compared with physician’s choice of single-agent chemotherapy in patients with previously treated metastatic triple-negative breast cancer.
Sacituzumab Govitecan Shows Sustained Activity in Heavily Pretreated Metastatic Urothelial Carcinoma
Sacituzumab govitecan-hziy continued to showcase significant activity with favorable tolerability in heavily pretreated patients with metastatic urothelial carcinoma who progressed on both platinum-based chemotherapy and checkpoint inhibition.
Updated Data Demonstrate Continued PFS and OS Benefit With Ripretinib in Advanced GIST
September 19th 2020The novel broad-spectrum KIT and PDGFRα inhibitor ripretinib continued to demonstrate clinically meaningful benefit as a fourth- or later-line treatment for patients with advanced gastrointestinal stromal tumors.
Nivolumab/Ipilimumab Combo Shows Durable Benefit at 4 Years in Advanced RCC
September 19th 2020The benefits conferred by the combination of nivolumab and ipilimumab for the first-line treatment of advanced renal cell carcinoma remained durable after 4-year follow-up compared with treatment with sunitinib.
First-in-Human Study of RO7122290 Shows Promise in Patients With Select Solid Tumors
September 19th 2020Safety and preliminary antitumor activity with the bispecific antibody RO7122290 alone or in combination with atezolizumab demonstrated preliminary antitumor activity and was safe for the treatment of patients with advanced solid tumors.
Balstilimab Monotherapy or Plus Zalifrelimab Active in Recurrent/Metastatic Cervical Cancer
The investigative PD-1 inhibitor balstilimab as a single agent and combined with the CTLA-4 inhibitor zalifrelimab showed promising objective response rates, regardless of PD-L1 expression, and a tolerable safety profile in patients with recurrent/metastatic cervical cancer.
PD-L1 Status Guides TIL activity in NeoTRIPaPDL1
September 19th 2020Although atezolizumab did not improve pathological complete response when added to carboplatin and nab-paclitaxel, the immunotherapy increased the pCR by 10% or more in “immune-rich” groups with high-risk and locally advanced triple-negative breast cancer, and also turned PD-L1 negative tumors positive in most immunotherapy-treated patients.
Nivolumab/Cabozantinib Combo Doubles PFS in Frontline RCC
The combination of nivolumab and cabozantinib led to a 49% reduction in the risk of disease progression or death, while also significantly improving overall survival and doubling objective response rate, compared with sunitinib in the first-line treatment of patients with advanced renal cell carcinoma.
Updated Data Shows Xevinapant Significantly Improves OS in Locally Advanced Head and Neck Cancer
September 19th 2020Three-year follow-up data for the phase 2 study of the first-in-class inhibitor of apoptosis protein antagonist, xevinapant, in combination with standard cisplatin-based concomitant fractionation chemoradiation therapy reduced the risk of mortality by half compared with CRT alone in patients with locally advanced squamous cell carcinoma of the head and neck.
Avelumab as Frontline Maintenance Improves OS Across Advanced Urothelial Carcinoma Subgroups
Frontline maintenance treatment with avelumab plus best supportive care improved both progression-free and overall survival compared with BSC alone across prespecified subgroups of patients with advanced or metastatic urothelial carcinoma that has not progressed on first-line platinum-based chemotherapy.
Despite Early Response, Frontline Avelumab Falls Short in Metastatic Urothelial Carcinoma
September 18th 2020Despite observed responses, induction therapy with avelumab prior to standard of care gemcitabine/carboplatin fails to sustain clinically meaningful efficacy and is not an adequate strategy for the first-line treatment for patients with metastatic urothelial carcinoma.
Novel PD-1/PD-L1 Inhibitor Combo Promotes Antitumor Activity in Urothelial Carcinoma
September 18th 2020The investigational PD-L1 inhibitor BGB-A333 in combination with the PD-1 inhibitor tislelizumab demonstrated marked antitumor activity, durable clinical responses, and a tolerable safety profile in patients with urothelial carcinoma.
Ipatasertib/Chemotherapy Combo Falls Flat in HR+ HER2- Advanced Breast Cancer
September 18th 2020The addition of ipatasertib to paclitaxel failed to improve progression-free survival and objective response rates versus placebo plus paclitaxel in patients with PIK3CA/AKT1/PTEN-altered hormone receptor–positive, HER2-negative advanced breast cancer.